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Abstract
Hepatitis E virus (HEV) is the most common cause 
of  acute viral hepatitis in the developing world. It is a 
waterborne virus that can cause epidemics in the face of  
overcrowding and poor sanitation. Although the hepatitis 
illness is usually self-limiting, it has a high mortality in 
pregnant women and can become a chronic infection in 
the immunosuppressed. Treatment is mostly supportive 
and prevention is by good water hygiene.
Introduction
Before the discovery of  hepatitis E virus (HEV), many 
epidemics of  hepatitis in the developing world were 
found to be from a cause other then the known hepatitis 
A, B and C viruses. HEV was discovered in 1983 in the 
stool samples of  a human volunteer infected with the 
combined stool samples of  patients with non-A, non-B 
hepatitis (Balayan et al., 1983). HEV is a small single-
stranded RNA virus spread by contaminated water. 
Epidemiology
HEV is the most common cause of  clinical hepatitis in 
many countries in Africa, including South Sudan, and 
Asia. There are four known genotypes of  HEV that can 
infect humans (Smith et al. 2013). Figure 1 illustrates the 
prevalence of  the different HEV genotypes across the 
world. It should be noted that there may be some inaccuracy 
in the epidemiology of  HEV due to the variation in the 
sensitivity of  various anti-HEV IgG testing kits and the 
lack of  standardization of  testing (Zhou et al., 2013).
Genotypes 1 and 2 affect humans alone. They are 
transmitted via the faecal-oral route and survive in water. 
Consequently, the places of  highest prevalence are areas 
of  over crowding and poor sanitation (Hazam et al., 2010). 
They are endemic in the developing world, with genotype 
1 being the most common cause of  HEV outbreaks. 
Notable outbreaks include the refugee camps in Maban 
County, South Sudan, 2012. 
Genotypes 3 and 4 affect humans and animals e.g. pigs, 
game. These genotypes are most commonly seen in 
the developed world, although low level prevalence of  
genotype 3 HEV has been found in locally farmed pigs in 
Cameroon (S de Paula et al., 2013). They are transmitted 
across species by consuming the raw or undercooked 
meat of  an infected animal (Tei et al., 2003, Emerson et 
al., 2005). Transmission may also occur rarely between 
humans. This has been documented by blood transfusions 
(Matsubayashi, 2004).
A further two more genotypes have been discovered that 
do not affect humans, but can infect wild boar (Smith et 
al., 2013).
Acute HEV infection
HEV infection can range from asymptomatic to 
fulminant hepatitis. The incubation period from infection 
to symptoms ranges from two to eight weeks (Purcell 
and Emerson, 2008). Symptoms include fever, fatigue, 
myalgia, arthralgia, weakness, vomiting, jaundice, pale 
stools and dark urine. Neurological symptoms, e.g. from 
peripheral neuropathy,may also occur (Kamar et al, 2011). 
Blood tests reveal raised liver transaminases, alkaline 
phosphatase, γ-glutamyltransferase and bilirubin.
Acute HEV infection can be diagnosed by the presence of  
anti-HEV IgM, whilst IgG suggests past infection. Due to 
the wide variation in the accuracy of  serological testing, 
viral Polymerase Chain Reaction (PCR) should be used to 
confirm the diagnosis (Drobenuic et al., 2010). 
In HEV endemic areas where HEV genotype 1 
predominates, only 20% of  HEV infections produce 
symptomatic hepatitis. HEV infection rarely causes 
clinical symptoms in children (Buti et al., 2008), in 
contrast to pregnant women who have the highest risk of  
symptomatic hepatitis.  
Pregnant women are a particularly susceptible group to 
HEV transmission, symptomatic infection and mortality. 
Mortality is 2% if  not pregnant and 20% if  pregnant 
(Rein et al., 2012). This mortality risk is most pronounced 
in the 3rd trimester when the mortality approaches 31% 
(Guthmann et al., 2006). The risk of  contracting acute 
HEV infection is increased by HIV infection in pregnancy 
(Caron et al., 2012). 
Pre-existing liver disease increases the risk of  fulminant 
hepatitis.  The mortality from HEV genotype 1 infection 
as a cause of  decompensation of  chronic liver disease 
is almost 70%, which is considerably higher than other 
causes of  decompensation (Kumar et al., 2004).
HEV infection only produces one symptomatic episode 
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due to the generation of  anti-HEV IgG antibodies. 
Chronic HEV
In the majority of  cases acute HEV infection will be 
cleared. An immunocompromised status may lead to the 
persistence of  the virus and chronic HEV infection. This 
is particularly the case for patients with HIV (Dalton 
et al., 2009), organ transplants (Kamar et al., 2008) and 
haematological malignancy. HEV infection in this group is 
more difficult to confirm as the standard antibody testing 
for HEV infection is unreliable due to the underlying 
immunocompromise and so direct molecular assays 
should be used. To date, only genotype 3 HEV has been 
shown to cause chronic infection.
Treatment
HEV infection is usually self-limiting and so only 
supportive treatment is needed. Severe infection can be 
treated with ribavirin, although ribavirin is contraindicated 
in pregnancy due to teratogenicity and fetal loss.  The 
approach to treating chronic infection in transplant 
patients is first to reduce the immunosuppression to allow 
clearance by the host (Kamar et al., 2010), then to treat 
with ribavirin and/or pegylated alpha interferon for three 
months if  infection remains (Scobie and Dalton, 2013).
Prevention and Vaccine
The main way to prevent HEV infection in developing 
countries is by maintaining good hygiene and to supply 
a safe water source. Chlorination of  water has not been 
shown to inactivate HEV (Guthmann et al., 2006), but 
boiling water will kill the virus (Emerson et al., 2005).
Human and animal studies have shown the development 
of  antibodies to HEV post infection that protect against 
re-infection (Bryan et al., 1994, Tsarev et al., 1994). 
Following subsequent work, two HEV vaccines have been 
developed.
The HEV 239 vaccine (Hecolin®) was shown to induce 
immediate immunity to HEV following two doses within 
one month with 100% efficacy against symptomatic 
HEV, lasting five months until the third dose (Shrestha 
et al., 2007). This supports its use in limiting an outbreak 
of  HEV. No adverse effects of  the vaccine have been 
observed in pregnancy (Wu et al., 2012) and its efficacy 
and safety have been confirmed in a phase III trial (Zhu et 
al., 2010). Pregnant women or women of  childbearing age 
could be targeted for vaccination in the face of  limited 
resources. The HEV 239 vaccine is currently licensed for 
use in China, but unfortunately is not part of  the WHO 
priority vaccines. 
Figure 1. Geographic distribution of human cases of Hepatitis E (Reprinted from The Lancet; 379(9835), Kamar et al., 2477–2488, Hepatitis 
E, Copyright 2012, with permission from Elsevier)
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Comparison with hepatitis A virus
There are many similarities between HEV and hepatitis A 
virus (HAV). Both HEV and hepatitis A virus (HAV) are 
enteric viruses spread by contaminated water. HAV is only 
found to infect human and non-human primates, whereas 
HEV has a wide variety of  zoonotic hosts, depending on 
its genotype (Purcell et al., 2008). The clinical presentation 
of  HEV is very similar to that of  HAV. There are only a 
few contrasting points. The incubation period of  HEV is 
roughly ten days longer than that of  HAV. The severity of  
disease and mortality tends to increase with age for HAV, 
whereas age has no bearing on HEV mortality. HEV does 
however, have a high mortality in pregnant women that 
is not seen in HAV. Finally, HAV hepatitis can relapse in 
contrast to HEV, which only causes a single episode of  
clinical illness.
Conclusion
HEV infection is a major cause of  morbidity in areas of  
over crowding and poor water hygiene. Pregnant women 
and patients with preexisting liver disease are most likely 
to develop fulminant hepatitis, with an associated high 
mortality. They could therefore be targeted for vaccination 
in endemic areas. Ultimately prevention of  transmission 
by good sanitation and boiling drinking water is the best 
approach to reduce morbidity and mortality from HEV 
and a number of  other waterborne pathogens.
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qUIz ANSWErS FOr OUr rEAdErS
Lady with fever and hepatomegaly
Case: A 54-year old female from an urban area presented 
with low grade fever, and vague right upper quadrant 
abdominal discomfort of  one month duration. She was a 
sweeper by profession and had no close contact with pets. On 
examination she was febrile; the vital signs were stable and 
she had no jaundice or other stigmata of  chronic liver disease. 
The liver was palpable to 7cms below the right costal margin 
and 4cms in the epigastrium with a smooth surface,and was 
tender to palpation: there were no bruits. Her haemogram 
and biochemical parameters were normal except for elevated 
alkaline phosphate levels (323 IU/L). These were the contrast 
enhanced computerized tomography images (see image).
Questions and answers:
Q1. What is the likely diagnosis?
A. Hydatid cyst of  liver.
Q2. What other conditions should be considered?
A. Liver abscess, biliary cystadenoma and hepatoma.
Q3. What is the most likely causative organism?
A. Echinococcusgranulosus.
Q4. What is the most serious complication of  this 
condition?
A. Rupture of  a cyst leading to anaphylactic shock.
Q5. Are there any serological tests that would aid 
diagnosis?
A. Enzyme-linked immunosorbent assay (ELISA): positive in 
90%.
Q6. What is the gold standard treatment of  the 
condition?
A. Surgical removal without disruption of  cyst contents.
Q7. Which is the preferred drug for the treatment of  the 
condition?
A. Albendazole.
Quiz sent by George Sarin Zacharia
This Book which costs £150 new  was donated to the South Sudan 
Postgraduate Medical Education &Training Library Juba by Dr. Peter 
Newman, Consultant Neurologist, James Cook University Hospital, 
Middlesborough. If  you have a reference textbook  which is less 
than five years old in Surgery, Medicine, Obstetrics & Gynaecology, 
Paediatrics & Child Health and Primary Health Care which you wish 
to donate to this newly established Library please email Dr. Eluzai 
Hakim with details on eluzaihakim@doctors.org.uk
